SecBot SecBot
PRESS-RELEASE ·Filed Jul 22, 2026

GNTA

GENENTA SCIENCE SPA
NEUTRAL
Impact 4/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor for any 6-K filing indicating Genenta exercises its option to increase Sòphia HT ownership to 51%, which would trigger consolidation and materially change GNTA's reported financials. Until then, this filing has limited direct impact on GNTA's stock.

DirectionNeutral
Confidencemedium
Horizonweeks
Final — all horizons settled through T+60d
GNTA ▼ -59.18% at T+60d
NEUTRAL call -59.18% · α vs SPY -62.44% · entry $1.64 → $0.6694
Entry = T+0 close
Jul 22, 2026
via day close
T+1d
+0.61%
call +0.61% · α +1.84%
$1.65
settled 3mo ago
T+5d
-20.73%
call -20.73% · α -18.33%
$1.30
settled 3mo ago
T+20d
-25.61%
call -25.61% · α -28.51%
$1.22
settled 2mo ago
T+60d
-59.18%
call -59.18% · α -62.44%
$0.6694
settled 12d ago

Price Chart

Loading chart...

Executive Summary

Genenta Science (GNTA) reported FY2025 results for its 19%-owned affiliate Sòphia HT, showing 29.3% sales growth to €7.17M and 68.1% EBITDA growth to €1.61M. However, these are unaudited, non-consolidated figures from an affiliate, not Genenta's own financials, making the direct read-through to GNTA's stock minimal. The filing primarily serves as a strategic update on Genenta's evolution into an aerospace/defense consolidator, with no standalone earnings data for GNTA itself.

Key Facts

  • Sòphia HT FY2025 sales rose 29.3% to €7.17M from €5.54M
  • Sòphia HT EBITDA grew 68.1% to €1.61M, margin expanded 380 bps to 19.0%
  • Genenta owns ~19% of Sòphia HT and does not consolidate its results
  • Genenta has contractual rights to increase ownership to 51% but no assurance of exercise
  • Sòphia HT appointed a new Board of Directors with Genenta representatives
  • Genenta is evolving into Saentra Forge, a strategic consolidator in aerospace/defense/biotech

Financial Impact

Sòphia HT FY2025 sales €7.17M, EBITDA €1.61M — not consolidated into GNTA financials

revenueebitda

Risk Factors

  • Sòphia HT financials are unaudited and not independently verified by Genenta
  • No assurance Genenta will exercise its option to consolidate Sòphia HT
  • Genenta's transition to Saentra Forge is subject to shareholder approval and closing risks

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3331105
15 reports for GNTA
Performance horizon
50% Hit rate @ T+60 2 of 4 directional calls Went positive at some point 6 of 7 best @ T+60▲ +154.23%Mar 27, 2026
Filters
Rows
Reports for GNTA — sortable, filterable
TypeNow
Oct 22, 2026
4d ago
6-K
NEUTRAL ★ 4/10
$0.6300awaiting T+60—$0.6192 (−1.71%)
Oct 21, 2026
5d ago
6-K
BEARISH ★ 6/10
$0.6301awaiting T+60—$0.6192 (+1.73%)
Oct 21, 2026
5d ago
Press Release
BEARISH ★ 7/10
$0.6301awaiting T+60—$0.6192 (+1.73%)
Oct 13, 2026
13d ago
6-K
BEARISH ★ 5/10
$0.6602awaiting T+60—$0.6192 (+6.21%)
Oct 7, 2026
19d ago
6-K
NEUTRAL ★ 4/10
$0.7101awaiting T+60—$0.6192 (−12.80%)
Oct 2, 2026
24d ago
SC 13D/A
NEUTRAL ★ 4/10
$0.7450awaiting T+60—$0.6192 (−16.89%)
Jul 22, 2026
13w ago
Press Release
NEUTRAL ★ 4/10
$1.64 $0.6694▼ −59.18%▼ −62.44%$0.6192 (−62.24%)
Jun 26, 2026
17w ago
6-K
NEUTRAL ★ 4/10
$1.80 $0.7040▼ −60.89%▼ −65.27%$0.6192 (−65.60%)
Jun 17, 2026
18w ago
6-K
NEUTRAL ★ 4/10
$1.84 $0.8408▼ −54.30%▼ −57.45%$0.6192 (−66.35%)
Jun 16, 2026
19w ago
6-K
BULLISH ★ 5/10
$1.87 $0.8613▼ −53.94%▼ −54.94%$0.6192 (−66.89%)
Showing 10 of 15

US Market Status

Market Open — Closes in 3h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 22, 2026